Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with type 1 diabetes

Article English OPEN
Marcovecchio , M. Loredana ; Widmer , Barry ; Dunger , David B. ; Dalton , R. Neil (2008)

International audience; Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is considered a major risk factor for cardiovascular disease and progression of renal disease. In the present study we aim to investigate the effect of acute va... View more
  • References (22)
    22 references, page 1 of 3

    1. Siroen, M.P., Teerlink, T., Nijveldt, R.J., Prins, H.A. and Richir, M.C. (2006) The clinical significance of asymmetric dimethylarginine. Annu. Rev. Nutr. 26, 203-228

    2. Böger, R.H. (2006) Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann. Med. 38, 126-136 T

    3. Kakimoto, Y. and Akazawa, S.(1970) Isolation and identification of NG, NG- and NG, N'G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and N glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J. BioIl. Chem. 245, 5751-5758

    4. McDermott, J.R. (1976) Studies on the catabolism of NG-methylarginine., RNG.,NGdimethylarginine and NG., NG'-dimethylarginine in the rabbit. Biochem. J. 154, 179- 184 P 5. Vallance, P., Leone, A., Calver, A., Collier, J. and Moncada, S. (-1992) Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 339, 572- 575 T

    6. Wahbi, N., Dalton, R.N., Turner, C., Denton, M., Abbs, I. and Swaminathan, R. (2001) Dimethlarginines in chronic renal failure. J. CSlin.Pathol. 54, 470-473

    7. MacAllister, R.J., Parry, H., Kimoto, M. et al. (1996) Regulation of nitric oxide synthesis by dimethylarginine dimethylaminoOhydrolase. Br. J. Pharmacol. 119, 1533- 1540

    8. Tran, C.T., Leiper, J.M. and Vallance, P. P(2003) The DDAH/ADMA/NOS pathway. Ather. Suppl. 4, 33-40

    9. Vallance, P. and Leiper, J. (2004) )Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler. Thromb. Vasc. Biol. 24, 1023a-1030

    10. Mookerjee, R.P., Dalton, (R.N., Davies, N.A. et al. (2007) Inflammation is an 2 important determinant of levels of the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver Transpl. 13, 400-405

    11. Siroen, M.P., Warlé, M.C., Teerlink, T. et al. (2004) The transplanted liver graft is capable of cleearing asymmetric dimethylarginine. Liver Transpl. 10, 1524-1530

  • Metrics
    No metrics available
Share - Bookmark